Companies › mAbxience Research
3 active drug programs in 3 registered trials: 3 Phase 3; Oncology, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MB11 PD-1 inhibitor (nivolumab biosimilar) | PDCD1 | Phase 3 | Advanced (Unresectable or Metastatic) Melanoma | Apr 2027 |
| MB12 PD-1 inhibitor | PDCD1 | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Sep 2027 |
| MB04 TNF-alpha inhibitor | TNF | Phase 3 | Rheumatoid Arthritis (RA) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06596772 | MB04 | Phase 3 | Rheumatoid Arthritis (RA) | Immunology | Feb 2026 |
| NCT07221734 | MB11 | Phase 3 | Advanced (Unresectable or Metastatic) Melanoma | Oncology | Apr 2027 |
| NCT06687369 | MB12 | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Oncology | Sep 2027 |
Lepu Biopharma BriaCell Therapeutics Innovent Biopharmaceutical Technology (Hangzhou) Taizhou Hanzhong biomedical Maia Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.